InvestSMART

Recce Pharmaceuticals Ltd (ASX: RCE) - Announcements

- Current share price for RCE : $0.330

ASX company news and announcements for Recce Pharmaceuticals Ltd (RCE) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Recce Pharmaceuticals Ltd (RCE) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Recce Pharmaceuticals Ltd (RCE), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Recce Pharmaceuticals Ltd (RCE)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$101 Appendix 4C and Activity Report 30 Jul 2021 12:20PM $0.950 $0.330 fallen by 65.26%
$101 Corporate Presentation 27 Jul 2021 12:10PM $1.035 $0.330 fallen by 68.12%
$101 Anti-Viral Patent Granted in USA for RECCE Anti-Infectives 22 Jul 2021 9:56AM $1.070 $0.330 fallen by 69.16%
$101 Anti-Viral Patent Granted in China 20 Jul 2021 11:24AM $0.935 $0.330 fallen by 64.71%
$101 Outstanding Efficacy Against Flesh-Eating Bacteria 19 Jul 2021 11:31AM $0.905 $0.330 fallen by 63.54%
$101 Multiple Patients Dosed in Topical Phase I/II Clinical Trial 12 Jul 2021 8:55AM $0.910 $0.330 fallen by 63.74%
$101 Bonus Canadian R&D Rebate Received 5 Jul 2021 2:37PM $0.950 $0.330 fallen by 65.26%
$101 Change of Director's Interest Notices - J Graham & M Dilizia 22 Jun 2021 9:33AM $0.990 $0.330 fallen by 66.67%
$101 Recce Pharmaceuticals to Present at World Microbe Forum 18 Jun 2021 9:50AM $1.020 $0.330 fallen by 67.65%
$101 Recce to Present at MST Access Investor Conference 17 Jun 2021 11:03AM $0.975 $0.330 fallen by 66.15%
$101 Corporate Presentation - EU Non-Deal Roadshow 7 Jun 2021 10:34AM $1.085 $0.330 fallen by 69.59%
$101 Recce Clinical Pipeline Update 7 Jun 2021 10:09AM $1.085 $0.330 fallen by 69.59%
$101 R327 Demonstrates World First Multiple Mechanisms of Action 27 May 2021 1:18PM $1.035 $0.330 fallen by 68.12%
$101 R327 to Stage 2 of SARS-CoV-2 Antiviral Screening at CSIRO 19 May 2021 1:44PM $1.100 $0.330 fallen by 70%
$101 Positive Data on RECCE 327 Against All Six ESKAPE Pathogens 4 May 2021 8:19AM $1.130 $0.330 fallen by 70.80%
$101 Appendix 4C and Activity Report 27 Apr 2021 10:28AM $1.090 $0.330 fallen by 69.72%
$101 RECCE 327 Registered for Topical Burns Study in Humans 15 Apr 2021 12:34PM $1.230 $0.330 fallen by 73.17%
$101 Positive Sinusitis Patient Update - Special Access Scheme 7 Apr 2021 10:09AM $0.980 $0.330 fallen by 66.33%
$101 Positive Sinusitis Data Against Infection 1 Apr 2021 9:30AM $0.965 $0.330 fallen by 65.80%
$101 Anti-Viral Patent Granted in EU for RECCE Anti-Infectives 30 Mar 2021 1:32PM $0.915 $0.330 fallen by 63.93%
$101 Pew Charitable Trusts adds R327 to Antibiotic Treatment List 15 Mar 2021 10:07AM $1.020 $0.330 fallen by 67.65%
$101 S&P DJI Announces March 2021 Quarterly Rebalance 12 Mar 2021 5:02PM $1.010 $0.330 fallen by 67.33%
$101 Recce Presenting at H.C. Wainwright Life Sciences Conference 10 Mar 2021 9:47AM $1.000 $0.330 fallen by 67%
$101 Recce Pharmaceuticals Dual Lists on Frankfurt Stock Exchange 8 Mar 2021 9:51AM $0.980 $0.330 fallen by 66.33%
$101 Change of Director's Interest Notice 25 Feb 2021 6:50PM n/a $0.330 n/a

351 - 375 of 730 results

Page 15 of 30

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.